A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01092832|
Recruitment Status : Terminated (This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any safety issues or concerns.)
First Posted : March 25, 2010
Results First Posted : August 17, 2015
Last Update Posted : June 23, 2016
|Condition or disease||Intervention/treatment||Phase|
|Candidiasis||Drug: voriconazole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||May 2013|
|Actual Study Completion Date :||June 2013|
Experimental: Active voriconazole
All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.
Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).
Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days.
Other Name: Vfend
- Percentage of Participants With Adverse Events - Overall Summary [ Time Frame: Baseline up to 1 month follow-up ]Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, who discontinued due to AEs, or who had dose redued or temporarily discontinued due to AEs.
- Percentage of Participants With a Global Response of Success at End of Treatment (EOT) [ Time Frame: EOT (from 7 to 42 days of treatment) ]Global response was determined programmatically based on investigator assessment of clinical and microbiological response. Global response of success was defined as clinical cure or improvement AND microbiological eradication or presumed eradication. Exact 95 percent (%) confidence interval for binomial proportions using Clopper-Pearson method.
- All-Cause Mortality - Number of Participant Deaths [ Time Frame: Day 28 and 1 Month Follow-up ]
- Time to Death [ Time Frame: Baseline up to 1 month follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092832
|Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology|
|Wuhan, Hubei, China, 430030|
|Beijing Children's Hospital, Capital University of Medical Sciences|
|Beijing, China, 100045|
|Fakultni nemocnice Brno - Klinika detske onkologie|
|Brno, Czech Republic, 625 00|
|Department of Paediatrics and Adolescent Medicine|
|Hong Kong, Hong Kong, 0|
|Queen Mary Hospital|
|Hong Kong, Hong Kong|
|The Chinese University of Hong Kong, Prince of Wales Hospital|
|Shatin, N.T., Hong Kong|
|Semmelweis Egyetem, II. sz. Szemeszeti Klinika|
|Budapest, Hungary, 1085|
|Semmelweis Egyetem, II. sz. Gyermekgyogyaszati Klinika|
|Budapest, Hungary, 1094|
|Fovarosi Onkormanyzat Egyesitett Szent Istvan és Szent Laszlo Korhaz-Rendelointezet|
|Budapest, Hungary, 1097|
|Instituto Nacional de Pediatria|
|Colonia Insurgentes Cuicuilco, Delegacion Coyoacan, DF, Mexico, 04530|
|Medical Research Laboratory Philippine General Hospital University of the Philippines|
|Ermita,, Manila, Philippines, 1000|
|Rm. 112 ICHHD, National Institutes of Health-University of the Philippines Manila|
|Manila, Philippines, 1000|
|Oddzial Pediatryczny I- Hematologiczno-Onkologiczny|
|Olsztyn, Poland, 10-561|
|Detska fakultna nemocnica s poliklinikou Bratislava|
|Bratislava, Slovakia, 833 40|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|